If you have ever been told by a doctor that hormone therapy should only be used at the lowest possible dose for the shortest possible time, you were given guidance that is no longer supported by the current evidence. In fact, it was never well-supported by the evidence it claimed to be based on.

This single phrase: "lowest dose, shortest time" has caused immeasurable harm. It has led generations of women to be undertreated, to stop therapy prematurely, to suffer unnecessarily through years of symptoms, and to miss a critical window of protection for their bones, brain, and heart.

It is time to retire it entirely.

Where This Guidance Came From

In 2002, the Women's Health Initiative, a large government-funded study, published results that sent shockwaves through medicine. Headlines declared that hormone replacement therapy caused breast cancer, heart disease, and stroke. Prescriptions plummeted almost overnight. The "lowest dose, shortest time" mantra became the standard of care, and it has persisted in clinical practice ever since.

But the study it was based on had fundamental problems that were not communicated to the public, or to most physicians, at the time.

The women enrolled in the WHI had an average age of 63. Many were more than a decade past menopause. They were not representative of the women most likely to be prescribed hormone therapy, women in their 40s and 50s experiencing the transition. The hormones used were oral conjugated equine estrogen and medroxyprogesterone acetate,  a synthetic progestin, not the transdermal bioidentical estradiol and micronized progesterone used in modern hormone therapy. And the results were applied broadly to all hormone therapy, all women, and all ages, a sweeping overcorrection that the data simply did not support.

The researchers who conducted the WHI have since acknowledged many of these limitations. The study's lead investigator herself later wrote that the findings were misinterpreted and misapplied. And in the two decades since publication, the evidence has consistently moved in one direction: toward recognizing that modern hormone therapy, started at the right time in the right women, is safe and beneficial.

What Changed: The FDA Black Box

In November 2025, the FDA initiated the removal of the black box warning from hormone therapy labeling. This is significant. The black box, which listed cardiovascular disease, breast cancer, and dementia as risks, had shaped how physicians talked about and prescribed HRT for more than twenty years.

The FDA stated that the goal was to provide current, accurate, and balanced information about the benefits and risks so that women in consultation with their healthcare providers can make the best decisions for their health. The agency specifically cited literature supporting risk reduction for all-cause mortality, fractures, heart attack, cognitive decline, and Alzheimer's disease with hormone therapy.

The removal of a black box warning is not a minor regulatory update. It is a formal acknowledgment that the evidence no longer supports the warnings as they were written.

What "The Lowest Dose" Actually Does to Your Body

The lowest effective dose sounds reasonable on the surface, why take more than you need? But the problem is that a dose low enough to treat symptoms may not be adequate to deliver the long-term health benefits that make hormone therapy about far more than hot flash relief.

Bone protection requires adequate estradiol levels. Research published in 2026 in Gynecological Endocrinology, based on data from the KEEPS and ELITE trials, found that optimal bone protection corresponds to serum estradiol levels of approximately 60 pg/mL. Below that threshold, a significant percentage of women continue to lose bone density even while on therapy. The most rapid bone loss of a woman's life occurs in the two years around the final menstrual period and a dose too low to reach therapeutic estradiol levels is not protecting her skeleton during the window when it matters most.

Cardiovascular benefit is dose dependent. The favorable effects of estradiol on lipids, hemostasis, and vasodilatation have been shown to require estradiol plasma concentrations at or above 57 pg/mL. A minimal dose that keeps symptoms tolerable may not be reaching the threshold where meaningful cardiovascular protection occurs.

Cognitive protection requires meaningful estrogen exposure. Estrogen is neuroprotective — it affects amyloid clearance, tau regulation, blood flow to the brain, and inflammatory pathways in the central nervous system. The emerging data on hormone therapy and Alzheimer's disease risk, including a 2026 study in Neurology showing 35% lower Alzheimer's pathology at autopsy in estrogen users, points toward meaningful hormonal exposure, not minimal exposure, as the relevant therapeutic target.

Undertreated symptoms are not a neutral outcome. Women who remain symptomatic on inadequate doses are not simply uncomfortable. Poor sleep compounds every other health outcome. Mood disruption affects relationships, work, and quality of life. Cognitive symptoms affect function and confidence. Treating to a dose that controls symptoms and reaches therapeutic tissue levels is not excessive, it is the point.

What "Shortest Time" Actually Does

The logic behind the shortest time guidance was that risk accumulates with duration, so limiting exposure limits risk. But this reasoning does not hold up under scrutiny when applied to modern transdermal hormone therapy.

Stopping therapy does not consolidate the benefits, it removes them. The bone density protection provided by estrogen therapy disappears when therapy is stopped. Women who discontinue HRT experience accelerated bone loss in the months and years following cessation, essentially returning to the trajectory they would have been on without therapy. The protection requires continuation.

Stopping and restarting is not safer than continuing. There is no evidence that cycling on and off hormone therapy carries a more favorable risk profile than sustained use. The disruption of stopping, with its rapid symptom recurrence and hormonal instability, carries its own consequences.

Symptoms return in the majority of women who stop. Studies consistently show that when hormone therapy is discontinued, the majority of women experience return of vasomotor symptoms, often within weeks. For many women, this return is worse than what they experienced before treatment. Stopping therapy is not a benign endpoint.

The cardiovascular and cognitive windows are time-sensitive. The timing hypothesis, supported by the KEEPS, ELITE, and multiple other trials, proposes that the protective effects of hormone therapy on the cardiovascular system and brain are greatest when therapy is initiated early in the transition and maintained. Stopping therapy during the critical window removes protection at exactly the time it is most needed.

What the Current Guidelines Actually Say

The Menopause Society, formerly the North American Menopause Society, has been explicit: there is no arbitrary maximum duration for hormone therapy. Decisions about how long to continue are driven by individual health factors, symptoms, risk factors, and personal goals, assessed in an annual review with a knowledgeable provider, not by a calendar date.

Their position is that for most healthy symptomatic women who are younger than 60 and within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. Women older than 65 can continue with appropriate counseling and monitoring. The question is never "how long is too long", it is "does this woman still benefit, and does she have a contraindication?"

The British Menopause Society, NICE, and other major international bodies align with this position. The lowest dose shortest time mantra appears nowhere in current evidence-based guidelines.

The Consequences of Under-Treatment

This is perhaps the most important reframe in modern menopause medicine. Undertreating hormone deficiency is not a neutral, conservative, safe option. It has consequences, and they are well-documented.

We know from surgical menopause data what happens when women are left without estrogen. Women who undergo hysterectomy with oophorectomy before natural menopause without receiving hormone therapy have a 70% higher risk of dementia, an 84% higher risk of cardiovascular death, and a 41% higher all-cause mortality compared to women who received estrogen therapy. These risks were concentrated in women who went untreated, not in those who were treated.

While surgical menopause is a more abrupt and complete hormonal loss than natural menopause, the underlying biology is the same. Estrogen deficiency carries risk. And the lowest dose shortest time approach, which leaves women at subtherapeutic levels or removes therapy entirely, is not protecting them from risk. It is exposing them to a different set of risks that medicine has been slow to acknowledge.

What We Do at The Lee Clinic

We do not prescribe hormone therapy based on a predetermined time limit or a reflexive commitment to the smallest possible dose. We prescribe based on the individual patient in front of us: her symptoms, her hormone levels, her risk factors, her health history, and her goals. We monitor levels, assess symptoms, and adjust as needed. We aim for doses that reach therapeutic tissue levels if possible, not the lowest dose that technically counts as treatment.

And when a patient is doing well on hormone therapy with no contraindications, we do not tell her it is time to stop because she has been on it long enough. We conduct an annual evaluation, discuss the benefit-risk picture honestly, and continue if continuing makes clinical sense.

That is individualized medicine. That is what the current evidence supports. And that is what every woman deserves.

The Lee Clinic sees patients in person in Winchester and Reston, VA. Telehealth appointments are available for patients in FL, DC, WV, and MD. Call us at 540-542-1700 to schedule.